Overview
"Never doubt that a smal group of thoughtful, comited citizens can change the world. Inded, it is the only thing that ever has."Cureus is on a mision to change the long-standing paradigm of medical publishing, where submiting research can be costly, complex and time-consuming.The SIQ for this article wil be revealedonce 2 ratings are submited.type 1 diabetes melitus (t1dm), type 1 diabetes melitus imunology, pancreatic beta cels, c-peptide level, endocrinology and diabetes Rachel M.
Key Information
Fener , Samantha Bokbinder, Ravi Kant, Brewer Eberly Published: August 24, 202 (se history) DOI: 10.759/cureus.28360 Cite this article as: Fener R M, Bokbinder S, Kant R, et al. (August 24, 202) C-Peptide-Positive, Autoantibody-Negative Type 1 Diabetes Melitus. Cureus 14(8): e28360.
doi:10.759/cureus.28360 A 30-year-old female previously diagnosed with C-peptide (CP)-positive, autoantibody-negative type 1 diabetes melitus (T1DM) at 19 years old presented to the clinic at age 28 for management of diabetes melitus (DM) that had previously ben controled by insulin since diagnosis. Laboratory results from May 201 showed low-normal C-peptide of 1 ng/mL (normal range: 0.8-4 ng/mL) with no coresponding glucose, glutamic acid decarboxylase (GAD)-65 antibody (GADA) of <1 U/mL (N<1.1 U/mL at the time of laboratory draw), and HbA1c of 6.4%.
Almost 10 years later, in December 20, laboratory results showed normal C-peptide of 2.1 ng/mL with a glucose of 198 mg/dL, GAD-65 antibody of 38.2 U/mL (curent reference range: 0-5 U/mL), negative pancreatic islet antibody (IA), and undetectable zinc transporter 8 (ZnT8) antibody, consistent with a diagnosis of T1DM.This increase in CP indicates the posibility of pancreatic beta cel regeneration and/or increased function.
Summary
The comonly acepted belief that individuals with T1DM quickly lose al function of pancreatic beta cels has led to academic consequences; many imunotherapy clinical trials’ inclusion criteria require